On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Dan Paterson, President and CEO of Verastem, Inc. (NASDAQ:VSTM), a clinical-stage biopharmaceutical company with a market capitalization of $273 million, recently sold 858 shares of the company's ...

Global markets have recently experienced a mix of volatility and growth, with U.S. stocks facing challenges from competitive pressures in the AI sector and political uncertainties surrounding tariffs, ...

The business is also an active participant with the retail giant's Project Gigaton. The initiative aims to engaging suppliers, NGOs and other stakeholders to remove 1 billion metric tons of greenhouse ...

Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.

BELVIDERE, NJ - Edible Garden AG Incorporated (NASDAQ:EDBL), a pioneer in controlled environment agriculture with a market capitalization of approximately $4 million, announced significant ...

Precision medicines biotech Frontier Medicines is leaving behind an unknown number of staffers as it refocuses resources to ...

Nanobubble Technology Potentially Increases Yield by 55% and Reduces Harvest Cycle by 30%, Revolutionizing Sustainable ...

For decades, scientists have tried to stop cancer by disabling the mutated proteins that are found in tumors. But many cancers manage to overcome this and continue growing. Now, scientists think they ...

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...

This nod to people whose main takeaway from Fight Club was how rad Brad Pitt's taste in shirts was is being sold by ZA/UM's ...

Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in mutated, wild-type, non-HER2-amplified ...